Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001999371-25-004117·Affinity Asset Advisors, LLC
Schedule 13G ownership disclosure
Karyopharm Therapeutics Inc
Common Stock, par value $0.0001 per share · CUSIP: 48576U205
Event date: 2025-04-03
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Affinity Healthcare Fund, LP
Shares: 664,224.00 · Class: 7.83%
- Affinity Asset Advisors, LLC
Shares: 664,224.00 · Class: 7.83%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001999371-25-004117
- Form type
- SCHEDULE 13G
- Filer
- Affinity Asset Advisors, LLC
- CIK
- CIK 1773195
- Filed
- Apr 10, 2025
- Reporting period
- Apr 03, 2025
- Description
- Schedule 13G beneficial ownership